Patents Issued in December 17, 2024
  • Patent number: 12168039
    Abstract: The present invention relates to a method of treating autoimmune disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.
    Type: Grant
    Filed: August 9, 2023
    Date of Patent: December 17, 2024
    Assignee: GemVax & KAEL CO., LTD.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 12168040
    Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: December 17, 2024
    Assignee: The Rockefeller University
    Inventors: David Bikard, Luciano Marraffini
  • Patent number: 12168041
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: December 17, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
  • Patent number: 12168042
    Abstract: Disclosed herein are circular zymogens of RNase 1 that have a proteolytic cleavage site and are activated by a specific protease. These circular zymogens are useful for treatment of disorders that are characterized by a specific protease (e.g., HTV-1 protease).
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: December 17, 2024
    Assignees: Massachusetts Institute of Technology, Wisconsin Alumni Research Foundation
    Inventors: Ronald Raines, Ian Windsor
  • Patent number: 12168043
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: December 17, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 12168044
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: December 17, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Oliver Schoor, Andrea Mahr
  • Patent number: 12168045
    Abstract: A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: December 17, 2024
    Assignee: Ultimovacs ASA
    Inventors: Gustav Gaudernack, Audun Tornes
  • Patent number: 12168046
    Abstract: The present disclosure relates, at least in part, to mycobacterial polynucleotides and polypeptides, to fragments or variants thereof, to cells comprising the mycobacterial polynucleotides and polypeptides, to cells comprising the mycobacterial polynucleotides and polypeptides, that are engineered to expand T-cells ex vivo, and to methods of use thereof.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: December 17, 2024
    Assignee: Children's National Medical Center
    Inventors: Michael Keller, Catherine Bollard, Patrick Hanley, Conrad Russell Cruz, Haili Lang, Shabnum Patel
  • Patent number: 12168047
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: December 17, 2024
    Assignee: International AIDS Vaccine Initiative, Inc.
    Inventors: Dominick Laddy, Danilo Casimiro, Thomas Evans, Megan Fitzpatrick Forrest, Nathalie Cadieux
  • Patent number: 12168048
    Abstract: Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
    Type: Grant
    Filed: May 16, 2024
    Date of Patent: December 17, 2024
    Assignee: NantCell, Inc.
    Inventor: Patrick Soon-Shiong
  • Patent number: 12168049
    Abstract: The present invention provides for modified Flavivirus such as a modified Zika virus. The modification according to various aspects of the invention results in reduced viral proteins compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region, or the nonstructural protein 3 (NS3) region or both the E and NS3 regions can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flavivirus are used as vaccine compositions to provide a protective immune response.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 17, 2024
    Assignee: Codagenix Inc.
    Inventors: John Robert Coleman, Steffen Mueller, Ying Wang
  • Patent number: 12168050
    Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: December 17, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Kim Ellen Schwendt, Benjamin Petsch
  • Patent number: 12168051
    Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.
    Type: Grant
    Filed: September 12, 2022
    Date of Patent: December 17, 2024
    Assignees: BIONTECH SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Mahjoub Bihi, Ugur Sahin, Mustafa Diken, Thorsten Klamp
  • Patent number: 12168052
    Abstract: Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: December 17, 2024
    Assignee: ImmunityBio, Inc.
    Inventor: Patrick Soon-Shiong
  • Patent number: 12168053
    Abstract: The present invention relates to a microneedle system (MNS for short) for the intradermal application of a hepatitis vaccine, namely the antigen HBsAg.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: December 17, 2024
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Andreas Henning, Heiko Spilgies
  • Patent number: 12168054
    Abstract: The present disclosure relates to a combination of an anti-CSF-1R antibody or anti-CSF-1 antibody or antigen binding fragment thereof or an inhibitor of CSF-1R activity and an HDAC inhibitor, e.g., entinostat, and methods of using the combination for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: December 17, 2024
    Assignee: Syndax Pharmaceuticals, Inc.
    Inventors: Peter Ordentlich, Lei Wang
  • Patent number: 12168055
    Abstract: An improved method for MRI-guided sonosensitized focused ultrasound treatment of malignant tissue is disclosed herein.
    Type: Grant
    Filed: February 22, 2024
    Date of Patent: December 17, 2024
    Assignee: SonalaSense, Inc.
    Inventor: Stuart L. Marcus
  • Patent number: 12168056
    Abstract: There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: December 17, 2024
    Assignee: The Regents of the University of California
    Inventors: Milan T. Makale, Wolfgang J. Wrasidlo, Santosh Kesari, Joanna McKittrick, Gustavo A. Hirata Flores, Olivia Graeve
  • Patent number: 12168057
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: December 17, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang
  • Patent number: 12168058
    Abstract: The present disclosure relates to novel glutarimide-containing compounds with KRAS mutant form degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: December 17, 2024
    Assignee: Tiger Biotherapeutics, Inc.
    Inventors: Ji Liu, Robert Luo, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian
  • Patent number: 12168059
    Abstract: Provided herein are oligonucleotides, trimeric peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease in a subject in need thereof, comprising administering to the subject oligonucleotides, trimeric peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: December 17, 2024
    Assignees: Sarepta Therapeutics, Inc., Massachusetts Institute of Technology
    Inventors: Justin Wolfe, Colin M. Fadzen, Bradley L. Pentelute, Gunnar J. Hanson
  • Patent number: 12168060
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: December 17, 2024
    Assignees: IntoCell, Inc., Y-Biologics Inc.
    Inventors: Taekyo Park, Sunyoung Kim, Suho Park, Doohwan Jung, Donghoon Seo, Sangkwang Lee, Sanghyeon Yun, Jihyeon Ha, Hyang Sook Lee, Okku Park, Beomseok Seo, Sena Kim, Minah Seol, Jina Song, Sung Ho Woo, Jongun Cho, Jaeho Lee, Hyun Mi Lee, Jae Eun Park, Youngja Song, Eunjin Lee, Hyun Ju Lee, Eun-Young Shim, Yunjung Ko, Minju Lee, Young woo Park, Yosup Rew
  • Patent number: 12168061
    Abstract: The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: December 17, 2024
    Assignee: CRAGE MEDICAL CO., LIMITED
    Inventors: Huamao Wang, Bo Song
  • Patent number: 12168062
    Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: December 17, 2024
    Assignee: EmendoBio Inc.
    Inventors: Lior Izhar, David Baram, Joe Georgeson, Michal Golan-Mashiach, Asael Herman, Rafi Emmanuel
  • Patent number: 12168063
    Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
    Type: Grant
    Filed: April 19, 2024
    Date of Patent: December 17, 2024
    Assignee: Advanced Accelerator Applications SA
    Inventors: Donato Barbato, Clementina Brambati, Daniela Chicco, Francesco de Palo, Lorenza Fugazza, Maurizio Mariani, Giovanni Tesoriere
  • Patent number: 12168064
    Abstract: One of the purposes of the present invention is to provide an aqueous dispersion for cosmetics comprising black iron oxide, which has excellent dispersion stability, scarcely causes clogging to a pen type container for a long period of time, achieves good color development as a liquid cosmetic, and is capable of imparting the resulting film with water resistance. The other purpose of the present invention is to provide a liquid cosmetic comprising the aqueous dispersion. The present invention provides an aqueous dispersion comprising a black iron oxide, water and hydroxypropylmethyl cellulose phthalate, wherein the black iron oxide is surface-silylated with an alkyltriethoxysilane. The present invention further provides a method for preparing an aqueous dispersion containing the black iron oxide having a surface-silylated with an alkyltriethoxysilane.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: December 17, 2024
    Assignees: JO COSMETICS CO., LTD., NISSIN CHEMICAL INDUSTRY CO., LTD.
    Inventors: Shogo Kato, Kentaro Watanabe
  • Patent number: 12168065
    Abstract: The present invention relates to a cosmetic composition for UV protection and, specifically, to a cosmetic composition for UV protection comprising: a sunscreen having a methoxycinnamate structure; and a specific weight of polar oil. The cosmetic composition for UV protection of the present invention significantly increases UV protection efficiency when exposed to UV light and has a remarkably excellent skin feel.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: December 17, 2024
    Assignee: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Min-Sung Choi, Kyung-Hee Song, Hyeong-Jin Cho
  • Patent number: 12168066
    Abstract: A hair care composition is disclosed comprising from 0.5 to 45% by weight of a salt of acyl glutamate and an anti-dandruff agent of piroctone olamine, wherein the salt of acyl glutamate and the anti-dandruff agent are present in a weight ratio of from 5:1 to 50:1, and wherein the composition does not comprise other anionic surfactants in addition to the salt of acyl glutamate.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: December 17, 2024
    Assignee: Conopco, Inc.
    Inventors: Shaokun Chang, Jian Liu, Yingying Pi, Xia Zheng
  • Patent number: 12168067
    Abstract: A composition includes polydatin and at least one photoisomerization stabilizer and cosmetically acceptable carrier. The at least one photoisomerization stabilizer confers photostabilization to trans-polydatin by at least about 5%, relative to an otherwise identical composition without the at least one photoisomerization stabilizer.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: December 17, 2024
    Assignee: L'OREAL
    Inventors: Brian Scott Bodnar, Simon Pierre Donck, Jun Suzuki, Cherry Wang
  • Patent number: 12168068
    Abstract: Provided are: a hydrophilized organic powder that is obtained by a hydrophilization treatment of a hydrophobic organic powder and has favorable properties; and a cosmetic that includes the hydrophilized organic powder. A hydrophilized organic powder that has a hydrophilizing-coat of polyoxyethylene (10) isostearyl ether on a hydrophobic organic powder is provided. Further, a cosmetic that includes the hydrophilized organic powder is provided. The hydrophobic organic powder is preferably an organic resin powder or a metallic soap powder, or a combination thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: December 17, 2024
    Assignee: MIYOSHI KASEI, INC.
    Inventor: Yukio Hasegawa
  • Patent number: 12168069
    Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.
    Type: Grant
    Filed: January 30, 2024
    Date of Patent: December 17, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip P. Mehta, Henil Alpeshbhai Patel, Jayanta Kumar Mandal
  • Patent number: 12168070
    Abstract: Provided herein are transmucosal and transdermal delivery systems comprising: at least one non-ionic surfactant; at least one polyol; and at least one active agent; and optionally further comprising at least one oil. In particular embodiments, the delivery system has an average particle size of from about 5 nm to about 200 nm.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: December 17, 2024
    Assignee: Medlab Clinical U.S., Inc.
    Inventors: David A. Rutolo, Jr., Sean Michael Hall, Luis Vitetta, Yusi Zhou, Samantha Maree Coulson
  • Patent number: 12168071
    Abstract: Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl diketopiperazine.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: December 17, 2024
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Liang Guo, Patrick Poisson, Susovan Jana
  • Patent number: 12168072
    Abstract: The present disclosure provides methods and systems for optically-induced auto-encapsulation. A method of the present disclosure comprises providing a media chamber comprising a medium comprising (i) a three-dimensional (3D) object comprising a photo-emitter, (ii) at least one polymeric precursor, and (iii) a photoinitiator, and subjecting the medium in the media chamber to a stimulus (e.g., an energy beam or a chemical stimulus) to induce photo-emission from the photo-emitter to trigger the formation of a polymer matrix from the at least one polymeric precursor, which polymer matrix at least partially encapsulates the 3D object.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: December 17, 2024
    Assignee: PRELLIS BIOLOGICS, INC.
    Inventors: Melanie P. Matheu, Erik Busby, Christopher Rogers, Milad Khorrami
  • Patent number: 12168073
    Abstract: A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: December 17, 2024
    Assignees: DONG-A ST CO., LTD., KM TRANSDERM LTD.
    Inventors: Sun-Woo Jang, Chang-Yell Shin, Hae-Sun Kim, Kwang-Ho Cha, Hyun-Jung Kim, Masaoki Goto
  • Patent number: 12168074
    Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: December 17, 2024
    Assignees: LTS LOHMANN Therapie-Systeme AG, DDP Specialty Electronic Materials US 9, LLC
    Inventors: Marco Emgenbroich, Eva-Marie Prinz, Elke Klein, Heike Kluth, Xavier Thomas, Linda Sue Nartker
  • Patent number: 12168075
    Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.
    Type: Grant
    Filed: May 4, 2023
    Date of Patent: December 17, 2024
    Assignee: Corium, LLC
    Inventors: Eun Soo Lee, Amit K. Jain, Parminder Singh
  • Patent number: 12168076
    Abstract: To prevent or suppress roughness of the skin of a wearer by configuring an absorbent article so as to quickly absorb a body fluid into an absorber, for example, configuring a diaper so as to quickly absorb loose stool into an absorber. An absorbent article includes a liquid-holding absorber and a liquid pervious top sheet on a skin-facing surface side of the absorber. An absorbent Q mainly containing glycerin is provided on an intermediate sheet that transfers at least a body fluid that has passed through the top sheet to the absorber.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: December 17, 2024
    Assignee: Daio Paper Corporation
    Inventor: Chihiro Kato
  • Patent number: 12168077
    Abstract: A system for monitoring an excimer bulb includes a thermoelectric energy harvester configured to be located adjacent to the excimer bulb and to convert thermal energy from the excimer bulb into electrical energy having a voltage. The system further includes a controller in electrical communication with the thermoelectric energy harvester and configured to calculate at least one of a remaining useful life of the excimer bulb or a current temperature of the excimer bulb based on the voltage of the electrical energy converted by the thermoelectric energy harvester.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: December 17, 2024
    Assignee: GOODRICH CORPORATION
    Inventors: Matthew Robert Pearson, Eric Johannessen
  • Patent number: 12168078
    Abstract: Embodiments of the disclosure include an uncovered ultraviolet light emitting panel for use in supporting instruments in an operating room. The panel fits inside an autoclave for sterilization and can be utilized without a sterile cover. In use, the panel irradiates surgical instruments and the nearby air continuously.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: December 17, 2024
    Inventor: John Mansell
  • Patent number: 12168079
    Abstract: Technologies for sanitizing medical devices are described. In particular, sanitizing systems, components of sanitizing systems, and methods for sanitizing medical devices such as continuous positive airway pressure (CPAP) equipment are described. In embodiments, the sanitizing systems include a sanitizing gas generator and a base including at least one exhaust port and a filter.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 17, 2024
    Assignee: SOCLEAN, INC.
    Inventors: Kurt Michael Maw, Ashley James Nye Legg, Robert Wilkins, Robert A. Charles, Alex Chaves
  • Patent number: 12168080
    Abstract: The arrangement for contamination-free introduction of a sterile object from a vessel, closed by means of a semipermeable cover, into a working chamber, surrounded by a wall, of a containment comprising a portal unit having an access flange arranged in the wall and forming a passage into the working chamber, and a door which sealingly closes the passage and which, in order to be opened, can be moved into the working chamber. The arrangement comprises a vessel receptacle having a repository for holding a vessel, an opening for introducing the vessel into the repository, and a flange for interacting with the access flange. A decontamination unit designed to, when the door is closed, the vessel receptacle is docked to the access flange and the vessel is stored in the vessel receptacle, decontaminate an outer surface of the cover. Based on this arrangement, a method for introduction is also disclosed.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: December 17, 2024
    Assignee: Pharma Integration S.R.L.
    Inventors: Robert Landes, Mathieu Müller, Kathrin Sprecher, Mike Zeller
  • Patent number: 12168081
    Abstract: Provided herein are compositions, systems and surgical methods for treating expandable soft tissue utilizing a reactive liquid hydrogel sealant mixture including a cross-linkable electrophilic compound, a nucleophilic compound, and an amphiphilic poly(alkyl)ene glycol block polymer in an amount of 20% (w/v) or less of the sealant composition. The composition can optionally include a viscosifier, in an amount of 0.1% to 1.0% (w/v) of the sealant composition.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: December 17, 2024
    Assignee: Ethicon, Inc.
    Inventors: Sai Veruva, Salim Ghodbane, Thomas Weindl
  • Patent number: 12168082
    Abstract: The present invention relates to a composition and a kit for regeneration and treatment of cartilage, preferably, fibrous cartilage or elastic cartilage and a regeneration method using the same. A composition and a kit for cartilage regeneration according to the present invention may be administered simply in a minimally invasive manner to a site in which fibrous cartilage or elastic cartilage is needed to be regenerated or restored from injury, exhibit resistance to degradation enzymes without toxicity within the body, and are attached to or detained at and thus retained at the injured, administered site, whereby behavioral improvement may be brought about in surrounding cells, which leads to effectively inducing defected tissues of the meniscus to be regenerated. Therefore, the composition of the present invention is useful as a mediator for aiding the regeneration of biological tissue defected regions in the biomaterials field.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 17, 2024
    Assignee: Medicrinia, Co., Ltd.
    Inventor: Seung Uk An
  • Patent number: 12168083
    Abstract: The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: December 17, 2024
    Assignee: GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER
    Inventors: Thomas Aper, Mathias Wilhelmi, Axel Haverich
  • Patent number: 12168084
    Abstract: The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further encase a composition comprising a cell or cells, such as for example, a stem cell. A single sheet can be folded over to encase a composition, or rolled to encase a composition with lamination at either end of the roll, for example. The invention also includes methods of using these articles to regenerate tissue at tissue defects, or heal wounds in damaged tissue.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: December 17, 2024
    Assignee: Elutia Med LLC
    Inventor: Robert G. Matheny
  • Patent number: 12168085
    Abstract: A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating includes a polymer, collagen, glycerin and a hemostatic agent. The polymer is selected from the group of polyhydroxybutyrate, polyglycerol sebacate and adducts of polyglycerol sebacate. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: December 17, 2024
    Assignee: Medtronic, Inc
    Inventors: Sean Chen, Kirsten R. Stark, Satish Pulapura, Kasyap V. Seethamraju, Jonathan T. Goodman, DanThanh H. Le
  • Patent number: 12168086
    Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate formed from a first material and a second material. At least one of the first and second materials includes a hemostatic agent. Kits, systems and methods are disclosed.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: December 17, 2024
    Assignee: Medtronic, Inc
    Inventors: Satish Pulapura, Fatima Buevich, Jorie S. Soskin, Franklin R. Mansfield, Kai R. Worrell, Charlie Wood, Jorge Alberto Trevino Blanco, Narvel M. Brooks, III
  • Patent number: 12168087
    Abstract: Blood from a blood source is drawn into a fluid flow circuit. A mononuclear cell product is separated from the blood, followed by at least a portion of the mononuclear cell product being conveyed into an electroporation device without disconnecting the blood source from the fluid flow circuit. The electroporation device opens pores in a membrane of at least one of the cells of the mononuclear cell product to allow DNA material (which is added to the mononuclear cell product prior to electroporation) to enter and modify the genome of the cell. At least a portion of the modified mononuclear cell product is returned to the blood source. The mononuclear cell product may be washed prior to being conveyed into the electroporation device. The modified mononuclear cell product may be washed after exiting the electroporation device.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: December 17, 2024
    Assignee: Fenwal, Inc.
    Inventors: Kyungyoon Min, Benjamin E. Kusters
  • Patent number: 12168088
    Abstract: A dialysis device implantable in a patient for dialysis includes a filtration unit. The filtration unit includes at least one dialysis chamber for containing and/or circulating dialysate; and at least one blood chamber for containing and/or circulating blood of the patient, disposed on at least one dialysis chamber and being in communication with the at least one dialysis chamber. Each of the at least one dialysis chamber and the at least one blood chamber comprise at least one inlet for circulating fluid into and/or out of the at least one dialysis chamber and the at least one blood chamber. The at least one dialysis chamber and the at least one blood chamber are configured such that the blood in the at least one blood chamber and the dialysate in the at least one dialysis chamber operably interact with each other for dialysis.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: December 17, 2024
    Assignee: NEPHRODITE LLC
    Inventors: Hiep Nguyen, Nikhil Shah, Julie Wilderman